CG Oncology/$CGON
1D1W1MYTD1Y5YMAX
Capital at risk
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Ticker
- $CGON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Dallas, United States
- Website
- cgoncology.com
CG Oncology Metrics
BasicAdvanced
$6.4B
-
-$2.72
0.23
-
Price and volume
Market cap
$6.4B
Beta
0.23
52-week high
$80.97
52-week low
$32.57
Average daily volume
702K
Financial strength
Current ratio
22.219
Quick ratio
21.776
Long term debt to equity
0.761
Total debt to equity
0.857
Profitability
EBITDA (TTM)
-249.663
Gross margin (TTM)
-2,593.69%
Net profit margin (TTM)
-3,602.68%
Operating margin (TTM)
-4,056.18%
Management effectiveness
Return on assets (TTM)
-17.67%
Return on equity (TTM)
-26.41%
Valuation
Price to revenue (TTM)
957.061
Price to book
6.21
Price to tangible book (TTM)
6.27
Price to free cash flow (TTM)
-33.235
Free cash flow yield (TTM)
-3.01%
Free cash flow per share (TTM)
-2.177
Growth
Revenue change (TTM)
1,030.31%
Earnings per share change (TTM)
53.47%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
Analyst projections of the future price of CG Oncology stock.
Bulls say / Bears say
HC Wainwright raised its price target on CGON to $100 from $80 and reiterated a Buy rating ahead of pivotal bladder cancer Phase 3 data, signaling increased analyst confidence in cretostimogene’s clinical potential (Reuters).
Publication of the pivotal Phase 3 BOND-003 Cohort C trial results in The Lancet Oncology demonstrated a ~75% complete response rate with durable outcomes and favorable safety in high-risk BCG-unresponsive NMIBC, validating cretostimogene’s efficacy profile (PubMed).
The company held approximately $1.0 billion in cash and equivalents at June 30, 2026, providing a funding runway through 2029 and reducing near-term financing risk for key regulatory and clinical milestones (Reuters).
Q2 2026 net loss widened to $79.1 million (USD 0.90 per share), up from prior periods, underscoring a high cash burn rate amid ongoing trial expenses (Reuters).
Q2 2026 EPS of −$0.90 missed consensus of −$0.66 by $0.24, reflecting weaker-than-expected financial results and potential analyst pessimism (Reuters).
Q2 2026 revenue was only $1.16 million, highlighting limited commercial traction and continued reliance on external financing for operations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
CG Oncology News
AllArticlesVideos
Funds containing CG Oncology
AllUSDEURGBP
Fund name | Fund size | $CGON weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.57% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.57% |
iShares Healthcare Innovation£DRDR | £1B | 0.57% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.45% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.